Amendments to the Claims

- **1. (Original)** A DNA or RNA localized in the cytoplasm having the 3'-terminus or 5'-terminus chemically modified with a group represented by the formula
 - -PO(OH)-O-CH₂CH₂OCH₂CH₂NH-CO-peptide or
 - -O-CO-NH-CH₂CH₂NHCONH(CH₂)₆NH-CO-NH-peptide.
- 2. (Currently amended) The DNA or RNA localized in the cytoplasm according to claim 1 modified with a wherein the peptide that is a signal peptide selected from HIV-1 Rev (SEQ ID NO: 1 in Sequence Listing), PKIα (SEQ ID NO: 2 in Sequence Listing), MAPKK (SEQ ID NO: 3 in Sequence Listing), and Dsk-1 (SEQ ID NO: 4 in Sequence Listing), or a membrane fusion peptide selected form an HIV-1 tat C-terminal membrane fusion peptide (SEQ ID NO: 5 in Sequence Listing), a gp-41 membrane fusion peptide (SEQ ID NO: 6 in Sequence Listing), an artificially designed amphipathic α-helical peptide (SEQ ID NO: 7 in Sequence Listing), and an artificially designed amphipathic β-sheet peptide (SEQ ID NO: 8, 14, or 15 in Sequence Listing).
- 3. (Currently amended) The DNA localized in the cytoplasm according to claim 1 or 2, wherein the DNA is an oligo DNA that exhibits a genetic medicinal activity.
- **4.** (Currently amended) The RNA localized in the cytoplasm according to claim 1 or 2, wherein the RNA is an oligo RNA that exhibits a genetic medicinal activity.

5-8. (Cancelled)

9. (Currently amended) A siRNA localized in the cytoplasm wherein characterized in that a chemical modification group is introduced into the 5'-terminus of at least one of the sense strand and the antisense strand constituting the double-strand or a dangling end of the antisense strand, or both.

- 10. (Currently amended) A siRNA localized in the cytoplasm wherein eharacterized in that at least one of the sense strand and the antisense strand contains a chemical modification group at a non-terminal position.
- 11. (Currently amended) The siRNA localized in the cytoplasm according to claim 9 or 10, wherein the chemical modification group has a polyamine molecule bonded thereto.
- **12.** (Currently amended) The siRNA localized in the cytoplasm according to claim 9 or 10, wherein the chemical modification group is a nuclear export signal peptide or membrane fusion peptide introduced via a bifunctional linker.
- **13.** (**Original**) The siRNA localized in the cytoplasm according to claim 12, wherein the bifunctional linker is a residue of a divalent chemical modification group.
- 14. (New) The siRNA localized in the cytoplasm according to claim 9 or 10, wherein the chemical modification group has a polyamine molecule bonded thereto.
- **15. (New)** The siRNA localized in the cytoplasm according to claim 9 or 10, wherein the chemical modification group is a nuclear export signal peptide or membrane fusion peptide introduced via a bifunctional linker.
- **16.** (New) The siRNA localized in the cytoplasm according to claim 15, wherein the bifunctional linker is a residue of a divalent chemical modification group.